CVRx, Inc. (CVRX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.47-6.96%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · CVRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Gross margin was 87% for both the three months ended September 30, 2026, and September 30, 2025.
Stated in 2 of 3 supplied quarters. Management reported: “Gross margin was 87% for both the three months ended September 30, 2026, and September 30, 2025.” “Gross margin was 87% and 84% for the three months ended March 31, 2026 and March 31, 2025, respectively.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Gross margin was 87% for both the three months ended September 30, 2026, and September 30, 2025.”
“Gross margin was 87% and 84% for the three months ended March 31, 2026 and March 31, 2025, respectively.”
As of September 30, 2026, the Company had a total of 262 active implanting centers in the U.S., compared to 250 as of September 30, 2025.
Stated in 2 of 3 supplied quarters. Management reported: “Third Quarter 2026 Financial and Operating Results Revenue was $13.8 million for the three months ended September 30, 2026, a decrease of $0.9 million, or 6%, over the three months ended September 30, 2025.” “First Quarter 2026 Financial and Operating Results Revenue was $14.8 million for the three months ended March 31, 2026, an increase of $2.4 million, or 20%, over the three months ended March 31, 2025.” Revenue was $14.769 million in 2026-Q1.
“As of September 30, 2026, the Company had a total of 262 active implanting centers in the U.S., compared to 250 as of September 30, 2025.”
“Revenue generated in the U.S. was $13.7 million for the three months ended March 31, 2026, an increase of $2.4 million, or 22%, over the three months ended March 31, 2025.”
Operating Expense Reductions The Company has taken a comprehensive set of actions to reduce the baseline cost structure.
Stated in 2 of 3 supplied quarters. Management reported: “R&D expenses decreased $0.5 million, or 16%, to $2.7 million for the three months ended September 30, 2026, compared to the three months ended September 30, 2025.” “Operating Expense Reductions The Company has taken a comprehensive set of actions to reduce the baseline cost structure.” Operating income was $-13.045 million in 2026-Q3.
“Operating Expense Reductions The Company has taken a comprehensive set of actions to reduce the baseline cost structure.”
“Business Outlook For the full year of 2026, the Company maintained its revenue and expense guidance, and updated its guidance range for gross margin, as follows: · Total revenue between $63.0 million…”
The number of sales territories in Europe remained unchanged at five for the three months ended September 30, 2026.
Stated in 1 of 3 supplied quarters. Management reported: “The number of sales territories in Europe remained unchanged at five for the three months ended September 30, 2026.” “Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by the Company’s in-house market access team, which has increased from 31% in 2024 to 44% in 2025 and to 50% for the first two months of 2026.”
“The number of sales territories in Europe remained unchanged at five for the three months ended September 30, 2026.”
“With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with h…
Stated in 2 of 3 supplied quarters. Management reported: “BENEFIT-HF Clinical Trial Update On March 31, 2026, the first site was activated in the BENEFIT-HF trial and the first patient was enrolled in the second quarter of 2026.” ““With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure.””
““With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with h…”
“BENEFIT-HF Clinical Trial Update On March 31, 2026, the first site was activated in the BENEFIT-HF trial and the first patient was enrolled in the second quarter of 2026.”
Over the trailing year it converted 0.75x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.